Minireviews
Copyright ©The Author(s) 2020.
World J Hepatol. Dec 27, 2020; 12(12): 1136-1147
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1136
Table 5 Advantages and disadvantages of the antimicrobials used to treat spontaneous bacterial peritonitis due to gram-negative bacteria producing carbapenem-resistant Enterobacteriaceae
Antimicrobial agent
Advantages
Disadvantages
Ref.
Aminoglycosides (i.e. Plazomicin)Good activity against GNB producing ESβL, KPC, AmpC but not MβL enzymesHeterogeneous susceptibility high dose (toxicity)[49]
Polimixins (i.e. Colistin)Low resistance emergenceLow efficacy for Klebsiella spp. producing KPC enzymes[56]
FosfomicynModerate activity against MDR–CRERapid emergence of antibiotic resistance[59]
Glycylcycline (i.e. Tigecycline)Good activity against MDR–CREHigh dose (toxicity)[62]
Fluorocycline (i.e. Eravacycline)Broad spectrum activity (even if MDR and XDR pathogens). Active against the most common tetracycline-resistance mechanisms. High oral bioavailability. Safety and tolerabilityNot active on Pseudomonas spp. and Burkholderia spp.[63- 65]
β-lactams/β-lactamase inhibitors (i.e. ceftazidime/avibactam)Good activity against GNB producing ESβL, KPC, AmpC, OXA-48 and MβL. Safety and tolerabilityFrequent emergence of antibiotic resistance[67]
Carbapenem/β-lactamase inhibitors (i.e. meropenem/vaborbactam or Imipenem/cilastatin/relebactam)Good activity against GNB producing ESβL, KPC and AmpC. Outcome improvementNot active on GNB producing OXA-48 and MβL[79]
Monobactam/β-lactamase inhibitor (i.e. aztreonam/avibactam)Good activity against GNB producing ESβL, KPC, AmpC and OXA-48Recently approved[50- 52]
Siderophore cephalosporin (i.e. Cefidecol)Broad spectrum of activity against GNB, including MDR Enterobacteriaceae, Pseudomonas aeruginosa and A. baumanniiRecently approved[50]